Wound Healing: HBOT’s Strongest Clinical Evidence
Wound care accounts for roughly 60% of all insurance-covered HBOT sessions in the United States, making it the single largest clinical application. The evidence base is the most robust of any HBOT indication: multiple randomized controlled trials, large registry datasets, and consistent results across wound types. Here is what the numbers actually show.
Diabetic Foot Ulcer Outcomes: The Core Statistics
Diabetic foot ulcers represent the most studied wound type in HBOT research. The gold-standard evidence comes from the HODFU trial, a double-blind, sham-controlled RCT of 94 patients:
- Complete healing at 1 year: 52% HBOT vs 29% placebo (P = 0.03)6
- Per-protocol (more than 35 sessions completed): 61% vs 27% (P = 0.009)
- Number needed to treat (NNT): approximately 4–5 patients treated to heal one additional wound
| Outcome | HBOT + Standard Care | Standard Care Alone | Relative Benefit |
|---|---|---|---|
| Complete wound healing at 1 year | 52-61% | 27-29% | Roughly doubles healing rate |
| Overall healing (meta-analysis) | RR = 2.39 | Reference | 2.4x higher (P < 0.00001) |
| Major amputation rate | RR = 0.31 | Reference | 69% reduction (P < 0.00001) |
| Wound area at 2 weeks | 23.19% more reduction | Reference | Significant (P < 0.001) |
Sources: Oley 2024, Londahl 2010, Cruz 2021
Meta-Analysis Summary: What Pooled Evidence Shows
Multiple systematic reviews have reached consistent conclusions:234
| Study | Studies/Patients | Key Finding |
|---|---|---|
| Yang et al. 2025 (network meta-analysis) | 34 RCTs, 2,268 patients | HBOT ranked #1 for healing rate (SUCRA 0.814) and area reduction (SUCRA 0.730) |
| Oley et al. 2024 | 14 studies | Overall healing RR 2.39; major amputation RR 0.31 (69% reduction) |
| Sharma et al. 2021 | 14 studies, 768 patients | Complete healing OR 0.29; major amputation RR 0.60 (40% reduction) |
| Cruz et al. 2021 | 11 RCTs, 668 patients | Amputation OR 0.53; ulcer healing OR 4.00; wound area reduction 23.19% at 2 weeks |
Wagner Grade-Stratified Healing Statistics
The 2024 Oley meta-analysis stratified results by DFU severity using the Wagner grading system, showing dramatic effects at all severity levels:2
- Wagner Grade II: Healing RR = 21.11 (P = 0.002)
- Wagner Grade III: Healing RR = 19.58 (P = 0.003); minor amputation RR = 0.06 (94% reduction, P = 0.0004)
- Wagner Grade IV: Healing RR = 17.53 (P = 0.004); major amputation RR = 0.08 (92% reduction, P < 0.0001)
These are among the largest effect sizes reported for any adjunctive intervention in wound care.
Real-World Outcomes: The Largest Single-Center Study
A 2023 retrospective cohort study of 774 treatment courses (all wound types, not just DFU) at a single HBOT center found:8
- 61.0% healed completely
- 22.9% partially healed
- 5.3% deteriorated
- Wound surface area: median decreased from 4.4 cm² to 0.2 cm² (P < 0.01)
- Quality of life improved: 60 to 75 on a 100-point scale (P < 0.01)
- Median treatment cost: EUR 9,188
Factors associated with worse outcomes: fewer than 30 sessions and severe arterial disease.
Cost-Effectiveness in Wound Care
A Canadian health technology assessment modeled outcomes in a cohort of 65-year-old diabetic patients with DFU over a 12-year horizon:9
- HBOT: CND$40,695 per patient; 3.64 quality-adjusted life years (QALYs)
- Standard care alone: CND$49,786 per patient; 3.01 QALYs
- Result: HBOT saves approximately $9,000 per patient AND produces better outcomes (dominant strategy)
A below-knee amputation costs $40,000–$80,000 for surgery alone, plus $100,000+ in 5-year follow-up costs (prosthetics, rehabilitation, lost productivity, increased mortality). HBOT’s NNT of 4–5 to prevent one major amputation means treating 4–5 patients at a cost of $60,000–$150,000 prevents one amputation event costing $200,000+.
Wound Types and Response Rates
| Wound Type | Response Rate | Typical Sessions | Insurance Coverage |
|---|---|---|---|
| Diabetic foot ulcers (Wagner 3+) | 52-61% | 30-40 | Medicare covered |
| Venous stasis ulcers | 45-60% | 30-40 | Sometimes covered |
| Post-surgical wound dehiscence | 55-70% | 20-30 | Usually covered |
| Radiation soft tissue necrosis | 60-75% | 30-60 | Medicare covered |
| Compromised skin flaps/grafts | 70-85% | 20-30 | Medicare covered |
What Does the HBOT Protocol Look Like?
Standard wound care HBOT protocols:
- Pressure: 2.0-2.4 ATA in a hard chamber with 100% medical-grade oxygen
- Session duration: 90-120 minutes at treatment pressure (plus compression/decompression time)
- Frequency: Once daily, 5 days per week (session scheduling details)
- Course length: 30-40 sessions for most wound types, with reassessment at session 20
- Continuation criteria: Treatment continues only if measurable healing progress is documented
Medicare requires documentation of healing progress to authorize continuation beyond 30 sessions. Soft chambers (which reach only 1.3 ATA) are not effective for wound healing and are not covered by Medicare for this indication.
Why Wounds Respond to HBOT
HBOT addresses the fundamental pathophysiology of chronic wounds through multiple mechanisms:
- Oxygen delivery: Chronic wounds are hypoxic. HBOT delivers oxygen at 10-15x normal levels directly to wound tissue10
- Angiogenesis: Repeated HBOT sessions stimulate new blood vessel formation via VEGF upregulation11
- Collagen synthesis: Fibroblasts require adequate oxygen to produce collagen, essential for wound closure12
- Antimicrobial effect: High oxygen concentrations directly kill anaerobic bacteria and enhance white blood cell bacterial killing
- Stem cell mobilization: HBOT releases endothelial progenitor cells from bone marrow via nitric oxide pathways12
Sources
- Yang J et al. Comparative efficacy of gas therapy for DFUs using network meta-analysis. PeerJ. 2025;13:e19571. DOI: 10.7717/peerj.19571
- Oley MH et al. HBOT for Diabetic Foot Ulcers Based on Wagner Grading. Plast Reconstr Surg Glob Open. 2024;12(3):e5692. DOI: 10.1097/GOX.0000000000005692
- Sharma R et al. Efficacy of HBOT for diabetic foot ulcer. Sci Rep. 2021;11:2189. DOI: 10.1038/s41598-021-81886-1
- Cruz D et al. Role of HBOT in treatment of diabetic foot ulcers. Int Angiol. 2021;40(4):327-340. DOI: 10.23736/S0392-9590.21.04722-2
- Zhang Z et al. Efficacy of HBOT for DFU: updated systematic review. Asian J Surg. 2021;44(12):1616-1617. DOI: 10.1016/j.asjsur.2021.07.047
- Londahl M et al. HBOT Facilitates Healing of Chronic Foot Ulcers in Patients With Diabetes. Diabetes Care. 2010;33(5):998-1003. DOI: 10.2337/dc09-1754
- Kumar A et al. HBOT as adjuvant to standard therapy for DFU. J Anaesthesiol Clin Pharmacol. 2020;36(2):213-218. DOI: 10.4103/joacp.joacp_94_19
- Lalieu R et al. HBOT for Nonhealing Wounds: Long-term Retrospective Cohort Study. Adv Skin Wound Care. 2023;36(6):1-8. DOI: 10.1097/01.ASW.0000922696.61546.31
- Chuck A et al. Cost-effectiveness of adjunctive HBOT for diabetic foot ulcers. Int J Technol Assess Health Care. 2008;24(2):178-183. DOI: 10.1017/S0266462308080252
- Hajhosseini B et al. Hyperbaric Oxygen Therapy: Descriptive Review. Plast Reconstr Surg Glob Open. 2020;8(6):e3136. DOI: 10.1097/GOX.0000000000003136
- Huang X et al. Hyperbaric oxygen potentiates diabetic wound healing. Life Sciences. 2020;259:118246. DOI: 10.1016/j.lfs.2020.118246
- Goldstein L. Hyperbaric oxygen for chronic wounds. Dermatol Ther. 2013;26(5):375-378. DOI: 10.1111/dth.12053
Medical Disclaimer
The content on BaricBoost.com is for informational purposes only and is not intended as a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website.
Author
Seph Fontane Pennock is the founder of BaricBoost.com and Regenerated.com, a clinic directory for regenerative medicine serving 10,000+ providers across the United States. He previously built and sold PositivePsychology.com, which grew to 19 million users and became the largest evidence-based positive psychology resource on the web. Seph brings direct experience as an HBOT patient, having completed protocols at clinics across three continents while navigating mold illness, systemic inflammation, and autoimmune conditions. His treatment journey includes hyperbaric oxygen therapy, peptide protocols, NAD+ therapy, and consultations with specialists from Dubai to Cape Town to Mexico. This combination of entrepreneurial track record and lived patient experience shapes everything published on BaricBoost.com. Every article is grounded in peer-reviewed research, informed by real clinical encounters, and written for patients making high-stakes treatment decisions. Seph's focus is on bringing transparency, scientific rigor, and practical guidance to the hyperbaric oxygen therapy space.
